AGS, based in Paris, France, is a group of interrelated companies developing biomedicines based on extracellular vesicles from microalgae (MEVs) as a safe, targeted and highly versatile delivery system for innovative biologics, such as mRNA, siRNA, miRNA, proteins, peptides and oligonucleotides for a broad range of human diseases.

AGS-M, a contract development and manufacturing organization, produces the MEVs needed to support preclinical and clinical development of MEV-based product pipelines from AGS Therapeutics, and from pharmaceutical and other companies partnering with AGS.

AGS’ MEVs are derived from Chlorella, a 2-billion-year-old single-cell algae used for decades as a food supplement. AGS’ MEVs are easy to manufacture in large quantities with simple cell culture media production techniques that are both eco-friendly and easily scalable